HOTAIR: A key regulator of the Wnt/β-catenin signaling cascade in cancer progression and treatment

Hakami, Mohammed Ageeli; Hazazi, Ali; Abdulaziz, Osama; Almasoudi, Hassan Hussain; Alhazmi, Abdulfattah Yahya M.; Alkhalil, Samia S.; Alharthi, Nahed S.; Alhuthali, Hayaa M.; Almalki, Waleed Hassan; Gupta, Gaurav; Khan, Farhan R.

doi:10.1016/j.prp.2023.154957

Cited by 6 publications

(2 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of these lncRNAs are now known to play vital roles in various physiological processes [ 15 – 19 ]. For example, HOTAIR, one of the earliest reported lncRNAs [ 20 , 21 ], has been recognized as a significant oncogenic driver [ 22 – 25 ], contributing to tumor cellular signaling transduction [ 26 – 28 ], cancer metabolism reprogramming [ 29 – 32 ], and tumor metastasis [ 33 – 36 ]. Another notable lncRNA, H19, is known for its involvement in embryonic development and imprinting regulation [ 37 – 42 ].…”

Section: Introductionmentioning

confidence: 99%

Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

Liao,

Wang,

Yuan

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1’s multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

Liao,

Wang,

Yuan

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…The deregulation of HOTAIR is strongly related to cancer development and progression ( Table 1 ) ( Zhang et al, 2014 ; Liguori et al, 2021 ; Xin et al, 2021 ; Qu et al, 2023 ; Tufail, 2023 ; Zhou et al, 2023 ; Hakami et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

The role of HOTAIR in the modulation of resistance to anticancer therapy

Cantile,

Belli,

Scognamiglio

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Leading anti-tumour therapeutic strategies typically involve surgery and radiotherapy for locally advanced (non-metastatic) cancers, while hormone therapy, chemotherapy, and molecular targeted therapy are the current treatment options for metastatic cancer. Despite the initially high sensitivity rate to anticancer therapies, a large number of patients develop resistance, leading to a poor prognosis. The mechanisms related to drug resistance are highly complex, and long non-coding RNAs appear to play a crucial role in these processes. Among these, the lncRNA homeobox transcript antisense intergenic RNA (HOTAIR), widely implicated in cancer initiation and progression, likewise plays a significant role in anticancer drug resistance. It can modulate cell activities such as proliferation, apoptosis, hypoxia, autophagy, as well as epithelial-mesenchymal transition, thereby contributing to the development of resistant tumour cells. In this manuscript, we describe different mechanisms of antitumor drug resistance in which HOTAIR is involved and suggest its potential as a therapeutic predictive biomarker for the management of cancer patients.

show abstract